top of page

Senior Managing Director

John Stroh

John Stroh, Senior Managing Director has over 30 years of experience in senior management, operations, finance, investment banking and M&A, primarily in the medical technology space.


Prior to Boustead Securities, Mr. Stroh was a Managing Director and led the healthcare team at Tellson Securities. Prior to Tellson, Mr. Stroh was also CEO of Nanospectra, LeuKoDx and Purewick which was sold to Bard in 2017. Prior to this he was President, CEO and Director of NeoMatrix LLC, a breast cancer risk assessment medical device company based in Irvine, California. Prior to NeoMatrix Mr. Stroh was COO & CFO, of Kadmus Pharmaceuticals, a pharmaceutical development company that was sold to Schering-Plough. From 1984 until 2001, Mr. Stroh worked as a Managing Director and Vice President in the investment banking industry for Smith Barney, Shearson- Lehman Brothers, John Nuveen & Company and Piper Jaffray. During this period, he was instrumental in raising over $2 billion for client companies and consulted on over 100 M&A and strategic partnering transactions.


He is on the Board of Directors for Orange Coast Memorial Hospital where he is also Chairman of the Finance Committee.

Mr. Stroh graduated from Cal State University with a Bachelor of Degree in Finance and the UCLA Anderson School of Management with a Masters of Business Administration.

Holds FINRA Series 82 and 63 licenses.

bottom of page